| Name | Title | Contact Details |
|---|
Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).
Prolonging Life and Enhancing its Quality Technology to improve the health of your immune system Learn more about our technology AditxtScore™ AditxtReprogramming™ AditxtScore™
Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology.
DMC is leading the low cost sustainable transformation of multiple product markets.
Spectrum Sciences is a California, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.